Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Taysha Gene Therapies (TSHA) PT Lowered to $31 at Jefferies
April 1, 2022 8:46 AM EDTJefferies analyst Eun Yang lowered the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $31.00 (from $41.00) while maintaining a Buy rating.
The analyst commented, "Prioritization of several key pipeline programs is positive (vs prior >20 gene therapy programs in development),... More
Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c
March 31, 2022 7:35 AM EDTTaysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($1.32), $0.07 worse than the analyst estimate of ($1.25).
For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.
... More